Cardiovascular Risk Factor, Metabolic Syndrome, Obesity, Abdominal
Conditions
Brief summary
The study is aimed to assess the efficacy of animal, plant sources of omega-3 polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and cardiovascular disease.
Detailed description
More than four million people in Europe (47%) and more than 1.9 million people in European Union (EU) (40%) die of cardiovascular diseases (CVD) every year. CVD mortality in EU is 43% in women and 36% in men. In Central and Eastern Europe, much more people die of CVD than in Western, Northern and Southern European countries. The World Health Organization (WHO) states that number of deaths in Slovakia is much higher than in Western European countries, even higher than in V4 countries - Slovakia, Czech Republic, Poland and Hungary In the first stage of the project fatty acids will be analyzed with the focus on the ratio of omega-6 and omega-3 polyunsaturated fatty acids in fatty food for normal consumption and in nutritional supplements containing omega-3 polyunsaturated fatty acids. In the second phase of the project risk factors of cardiovascular diseases for people without and people with a history of cardiovascular disease will be monitored and compared. There will be monitored and compared a wide range of laboratory markers of clinical biochemistry, immunology, pathological physiology in order to determine cardiovascular risk for men and women in different age categories. The third stage will monitor the effect of natural plant and animal sources and pharmacological nutritional supplements with omega-3 polyunsaturated fatty acids on obesity, metabolic syndrome and cardiovascular risk factors. The aim of this study is to assess the efficacy of animal, plant sources of omega-3 polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and cardiovascular disease.
Interventions
DIETARY_SUPPLEMENTChia seeds supplementation (25 g)
Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
DIETARY_SUPPLEMENTChia seeds supplementation (15 g)
Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
DIETARY_SUPPLEMENTCombine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20
Chia seeds - 1 daily dose Fish oil TID Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg) On dose (15g) of chia seeds contains: energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
DIETARY_SUPPLEMENTFish oil supplementation
TID Daily dose: Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)
Sponsors
Pavol Jozef Safarik University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Healthy and obese people in different age categories.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* for obese participants were BMI≥29, age ≥18 and non-smokers, cardiovascular diseases. metabolic syndrome, obesity * for healthy participants with normal weight, inclusion criteria BMI25, age ≥18, non-smokers
Exclusion criteria
* for all participants were cancer, inflammatory diseases, tuberculosis, renal and hepatic insufficiency, and pregnancy * for healthy participants without cardiovascular diseases, obesity and metabolic syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body mass index | 6 months | BMI kg/m2 6 months change. |
| glucose levels | 6 months | fasting glucose in mmoL/L |
| Change in total cholesterol from baseline | 6 months | percentual change in total cholesterol (mmoL/L) from baseline to 6months followup \- total genetic analysis, extracellular DNA |
| Systemic inflammation activity | 1 months | Interleukin 1 levels, interleukin 6 levels (pg/mL) |
| Antioxidant status | 18 months | Determination of total antioxidant capacity (mmoL/L) |
| Change in estrogen concentration | 6 months | Assesment of concentration of estrogen (ng/mL) |
| Bile acids in serum | 6 months | Concentration of serum bile acids (pg/mL) |
| Tissue concentrations of nitric oxide | 6months | Determination of nitric oxide synthetase activity by electron microscopy |
| NF kappa B activity | 6 months | Determination of NF kappa B activity by electron microscopy |
| Catalase activity | 6 months | Determination of Catalase activity by electron microscopy |
| Superoxide dismutase activity | 6 months | Determination of Superoxide dismutase activity by electron microscopy |
Countries
Slovakia
Contacts
Primary ContactZdenka Hertelyová, Dr. PhD.
Backup ContactAlojz Bomba, MVDr., DrSc.
Outcome results
None listed